Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07540910 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT07540910 is a Phase 1 study that is actively recruiting participants, run by Enanta Pharmaceuticals. The registered enrollment target is 98 participants.
The verdict
NCT07540910, a Phase 1 study, is actively recruiting participants, sponsored by Enanta Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of EDP-978 in healthy adult subjects.
Interventions
- DRUG Placebo
- DRUG EDP-978
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07540910
The ClinicalTrials.gov registry entry for NCT07540910 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07540910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07540910 about?
NCT07540910 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults". This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of EDP-978 in healthy adult subjects.
What is the current status of trial NCT07540910?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2026-04-01. Estimated completion is 2026-11.
What interventions are being tested in trial NCT07540910?
The interventions under investigation include: Placebo (DRUG), EDP-978 (DRUG).
Who is sponsoring clinical trial NCT07540910?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.